Clinical Research Directory
Browse clinical research sites, groups, and studies.
Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients
Sponsor: Children's Hospital Medical Center, Cincinnati
Summary
The investigators hypothesize that graft rejection after hematopoietic stem cell transplant (HSCT) is primarily driven by interferon gamma, and prophylactic interferon gamma inhibition in high-risk patients will prevent graft rejection. Additionally, knowledge of emapalumab PK/PD and in vitro mechanistic effects of emapalumab in this novel setting will guide optimization of dosing regimens and treatment approaches in future studies.
Official title: Emapalumab for the Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2026-01-07
Completion Date
2029-08
Last Updated
2026-01-22
Healthy Volunteers
No
Interventions
Emapalumab 3 mg/kg
Subjects will be randomized to either receive a 3mg/kg or 10mg/kg intravenous dose of emapalumab once and may receive up to two additional doses if clinical concern for impending graft rejection develops.
Emapalumab 10 mg/kg
Subjects will be randomized to either receive a 3mg/kg or 10mg/kg intravenous dose of emapalumab once and may receive up to two additional doses if clinical concern for impending graft rejection develops.
Locations (1)
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States